Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease

Neurobiology of Disease

Volumn 4, Issue 3-4, 1997, Pages 186-200

  Björklund, Anders ^a   Rosenblad, Carl ^a   Winkler, Christian ^a   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN PROTECTION; DOSE RESPONSE; DRUG EFFECT; GROWTH STIMULATION; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0030725572     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1997.0151     Document Type: Article

References (53)

1. Barnéoud P., Parmentier S., Mazadier M., Miquet A., Boireau P., Dubédat P., Blanchard J.-C. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience. 67:1995;837-848.
2. Beck K. D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R. A., Rosenthal A., Hefti F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 373:1995;339-341.
3. Berger K., Przedborski S., Cadet J. L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal injection in rats. Brain Res. Bull. 26:1991;301-307.
4. Björklund A., Lindvall O. Catecholaminergic brain stem regulatory systems. Handbook of Physiology: The Nervous System. Vol. 4. Intrinsic Regulatory Systems in the Brain. 1986;American Physiological Society, Bethesda. p. 115-235.
5. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J., Granholm A-C. E. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
6. Bowenkamp K. E., David D., Lapchak P. L., Henry M. A., Granholm A.-C., Hoffer B. J., Mahalik T. J. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. Exp. Brain Res. 111:1996;1-7.
7. Bowenkamp K. E., Lapchak P. L., Hoffer B. J., Miller P. J., Bickford P. C. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp. Neurol. 145:1997;104-117.
8. Cadet J. L., Last R., Kostic V., Przedborski S., Jackson-Lewis V. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res. Bull. 26:1991;707-713.
9. Cadet J. L., Zhu S. M. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res. 595:1992;316-326.
10. Carli M., Evenden J. L., Robbins T. W. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature. 313:1985;679-682.
11. Choi-Lundberg D. L., Bohn M. C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Dev. Brain Res. 85:1995;80-88.
12. Cousins M. S., Sokolowski D., Salamone J. D. Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol. Biochem. Behav. 46:1993;943-951.
13. Cousins M. S., Salamone J. D. Involvement of ventrolateral striatal dopamine in movement initiation and execution: A microdialysis and behavioral investigation. Neuroscience. 70:1996;849-859.
14. Dunett S. B., Iversen S. D. Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum. Brain Res. 248:1982;121-127.
15. Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: Substantia nigra regional specificity. Brain. 114:1991;2283-2301.
16. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A. Functional recovery in Parkinsonian monkeys treated with GDNF. Nature. 380:1996;352-355.
17. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L-F. H., Gerhardt G. A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
18. Hudson J., Granholm A-C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F., Hoffer B. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36:1995;425-432.
19. Ichitani Y., Okamura H., Masamoto Y., Nagatsu I., Ibata Y. Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 549:1991;350-353.
20. Jenkins R., O'Shea R., Thomas K. L., Hunt S. P. c-jun expression in substantia nigra neurons following striatal 6-hydroxydopamine lesion in the rat. Neuroscience. 53:1993;447-455.
21. Johansson M., Friedemann M., Hoffer B. J., Strömberg I. Effects of glial cell line-derived neurotrophic factor on developing and mature mesencephalic grafts in oculo. Exp. Neurol. 134:1995;25-34.
22. Kearns C. M., Gash D. M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
23. Kelly P. H., Seviour P. W., Iversen S. D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
24. Kotzbauer P. T., Lampe P. A., Heuckeroth R. O., Golden J. P., Creedon D. J., Johnson E. M., Milbrandt J. Neurturin, a relative of glial cell line-derived neurotrophic factor. Nature. 384:1996;467-470.
25. Lapchak P. A. Therapeutic potentials for glial cell-line derived neurotrophic factor (ADNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7:1996;165-176.
26. Lapchak P. A., Miller P. J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience. 77:1997a;745-752.
27. Lapchak P. A., Miller P. J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery. Neuroscience. 78:1997b;61-72.
28. Lapchak P. A., Jiao S., Collins F., Miller P. J. Glial cell line-derived neurotrophic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res. 747:1997c;92-102.
29. Lee C. S., Sauer H., Björklund A. Dopaminergic neuronal degeneration and motor impairments following lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience. 72:1996;641-653.
30. Lin L-F. H., Doherty D. H., Lile J. D., Bektesh S., Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
31. Lindner M. D., Plone M. A., Francis J. M., Blaney T. J., Salamone J. D., Emerich D. F. Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behav. Brain Res. 86:1997;25-40.
32. Lindsay R. M. Neuron saving schemes. Nature. 373:1995;289-290.
33. Lu X., Hagg T. Glial cell line-derived neurotrophic factor (GDNF) prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J. Comp. Neurol. 1997.
34. Martin D., Miller G., Fischer N., Dix D., Cullen T., Russell D. Glial cell line-derived neurotrophic factor: The lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats. Eur. J. Neurosci. 8:1996;1249-1255.
35. McGeer P. L., Itagaki S., Akiyama H., McGeer E. G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24:1988;574-576.
36. Phillips H. S., Armanini M. P., Moffet B., Vandelen R., Johnson E., Milbrandt J., Nishimura M. Neurturin is expressed within the nigrostriatal system and promotes survival of injured nigral dopaminergic neurons in vivo. Soc. Neurosci. 1997.
37. Pochon N. A.-M., Menoud A., Tseng J. L., Zurn A. D., Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified byin situ. Eur. J. Neurosci. 9:1997;463-471.
38. Poulsen K. T., Armanini M. P., Klein R. D., Hynes M. A., Phillips H. S., Rosenthal A. TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic neurons. Neuron. 13:1994;1245-1252.
39. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togaski D. M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
40. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. J. Neural Transm. 38:1976;277-301.
41. Rosenblad C., Martinez-Serrano A., Björklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience. 75:1996;979-985.
42. Rosenblad C., Martinez-Serrano A., Björklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 1997a.
43. Rosenblad C., Kirik D., Klein R., Johnson E. M., Millbrandt J., Phillips H. S., Björklund A. Neurturin prevents delayed degeneration of nigral dopaminergic neurons following axon terminal lesion induced by intrastraital 6-hydroxydopamine. Soc. Neurosci. Abstract. 23:1997b;248.12.
44. Sabol K. E., Neill D. B., Wages S. A., Church W. H., Justice J. B. Dopamine depletion in a striatal subregion disrupts performance of a skilled motor task in the rat. Brain Res. 335:1985;33-43.
45. Sauer H., Rosenblad C., Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. 92:1995;8935-8939.
46. Sauer H., Oertel W. H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
47. Schaar D. G., Sieber B. A., Dreyfus C. F., Black I. B. Regional and cell specific expression of GDNF in rat brain. Exp. Neurol. 124:1993;368-371.
48. Shults C. W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport. 7:1996;627-631.
49. Strömberg I., Björklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 124:1993;401-412.
50. Tomac A., Lindqvist E., Lin L.-F. H., Ögren S. O., Young D., Hoffer B. J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
51. Trupp M., Belluardo N., Funakoshi H., Ibànez C. F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret Proto-Oncogene, and GDNF receptor-α indicates multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 17:1997;3554-3567.
52. Unsicker K. Growth factors in Parkinson's disease. Progress Growth Factor Res. 5:1994;73-87.
53. Winkler C., Sauer H., Lee C. S., Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.